Skip to main content
Premium Trial:

Request an Annual Quote

Naveen Kulkarni, Praveen Rajendra, Stephen David, Ofer Haviv, Hagai Karchi, Martin Gerstel, Leon Recanati, and Ilan Chet


Naveen Kulkarni, who previously led the bioinformatics division at India's SysArris, has joined Polyclone Bioservices as CEO. Praveen Rajendra has joined Polyclone as chief information officer. Rajendra was previously worked at Nitya Technologies, a software services company based in Bangalore.

Stephen David has joined Nonlinear Dynamics' strategic marketing team. Stephen joins Nonlinear from GE Healthcare, formerly Amersham Biosciences, where he served as DiGE global applications specialist, and helped develop GE Healthcare's DeCyder DiGE-specific 2D image analysis product.

Compugen subsidiary Evogene has promoted Ofer Haviv to president and CEO. Haviv was previously Evogen's COO and CFO. Hagai Karchi, who co-founded Evogene in 2002 and has served as CEO since that time, has been appointed CSO. The company also announced a number of changes to its board of directors: Martin Gerstel, chairman of Compugen, has been appointed chairman; Leon Recanati, chairman and CEO of GlenRock Israel, has been elected a director; and Ilan Chet, president of the Weizmann Institute, has been appointed as a special advisor to the board. Evogene also announced last week that it had received $1.75 million in new capital from its existing investors and new investors from Israel, France, and North America.

Filed under

The Scan

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.